Study design
Cancer
CANCER
The present, single-arm, nonrandomized, observational study was conducted at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from January 2019 to January 2022. All the data were collected and de-identified using an electronic data capturing system (Viedoc™, Pharma Consulting Group, Ltd.). An independent data and safety monitoring committee monitored the safety and progress of the trial.